Survey shows dangerous knowledge gaps in pancreatic cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

While pancreatic cancer rates are rising in people under age 50, a new survey conducted by The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute shows that most people continue to believe that pancreatic disease affects only elderly people—and that there is nothing they can do to...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Zoldonrasib, an oral RAS(ON) G12D-selective covalent inhibitor, in combination with daraxonrasib showed 81% objective response rate compared to zoldonrasib in combination with standard of care chemotherapy in previously untreated patients with RAS G12D metastatic pancreatic ductal adenocarcinoma, according to results of two phase I/II study. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login